$891.97K in average volume shows that Nurix Therapeutics Inc (NRIX) is heading in the right direction

On Monday, Nurix Therapeutics Inc (NASDAQ: NRIX) was -3.86% drop from the session before settling in for the closing price of $19.71. A 52-week range for NRIX has been $7.83 – $29.56.

During the last 5-year period, the sales growth of Healthcare Sector giant was 24.84%. When this article was written, the company’s average yearly earnings per share was at -9.76%. With a float of $73.81 million, this company’s outstanding shares have now reached $75.87 million.

Let’s determine the extent of company efficiency that accounts for 286 employees. In terms of profitability, gross margin is 77.77%, operating margin of -390.52%, and the pretax margin is -354.36%.

Nurix Therapeutics Inc (NRIX) Insider Activity

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Nurix Therapeutics Inc stocks. The insider ownership of Nurix Therapeutics Inc is 2.74%, while institutional ownership is 89.04%. The most recent insider transaction that took place on Jan 31 ’25, was worth 114,934. In this transaction Chief Legal Officer of this company sold 5,760 shares at a rate of $19.95, taking the stock ownership to the 32,538 shares. Before that another transaction happened on Jan 31 ’25, when Company’s Officer proposed sale 5,760 for $20.02, making the entire transaction worth $115,286.

Nurix Therapeutics Inc (NRIX) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.76 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -9.76% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.35% during the next five years compared to -38.86% drop over the previous five years of trading.

Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators

You can see what Nurix Therapeutics Inc (NRIX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.36.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.89, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -3.28 in one year’s time.

Technical Analysis of Nurix Therapeutics Inc (NRIX)

Looking closely at Nurix Therapeutics Inc (NASDAQ: NRIX), its last 5-days average volume was 0.66 million, which is a drop from its year-to-date volume of 0.67 million. As of the previous 9 days, the stock’s Stochastic %D was 38.44%. Additionally, its Average True Range was 1.10.

During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 12.02%, which indicates a significant decrease from 24.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.38% in the past 14 days, which was lower than the 54.66% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $20.26, while its 200-day Moving Average is $20.62. However, in the short run, Nurix Therapeutics Inc’s stock first resistance to watch stands at $19.52. Second resistance stands at $20.08. The third major resistance level sits at $20.49. If the price goes on to break the first support level at $18.54, it is likely to go to the next support level at $18.13. Should the price break the second support level, the third support level stands at $17.57.

Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats

There are 75,887K outstanding shares of the company, which has a market capitalization of 1.44 billion. As of now, sales total 76,990 K while income totals -143,950 K. Its latest quarter income was 12,590 K while its last quarter net income were -48,960 K.